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SUMMARY  
 
Background: Epidemiological studies have linked lifestyle, cardiometabolic, 
reproductive, developmental and inflammatory factors with colorectal cancer (CRC) 
risk. However, it is unclear which specific factors influence risk and the strength of 
effects.  
 
Methods: Under a random-effects model we examined the relationship between 39 
potentially modifiable risk factors and CRC using genetic variants as instruments 
using two-sample Mendelian randomisation (MR), thereby limiting bias from 
confounding and reverse causation. Using genetic data on 26,397 CRC patients and 
41,481 controls, we calculated odds ratios of CRC risk per genetically predicted 
standard deviation unit increase in each putative risk factor (ORSD). Evidence of MR 
assumption violation was sought using MR-Egger regression. A Bonferroni-corrected 
threshold of P=1.3x10-3 was considered significant, and P<0.05 considered suggestive 
of an association. 
 
Findings: No putative risk factors were significantly associated with CRC risk after 
correction for multiple testing. Suggestive associations were however seen between 
genetically predicted body fat percentage (ORSD=1.14, 95% confidence interval 
[CI]=1.03-1.25, P=0.0086), BMI (ORSD=1.09, 95% CI=1.01-1.17, P=0.023), waist 
circumference (ORSD=1.13, 95% CI=1.02-1.26, P=0.018) and basal metabolic rate 
(ORSD=1.10, 95% CI=1.03-1.18, P=0.0079) with higher CRC risk. Low-density 
lipoprotein cholesterol level (ORSD=1.14, 95% CI=1.04-1.25, P=0.0056) and circulating 
serum iron (ORSD=1.17, 95% CI=1.00-1.36, P=0.049) also showed suggestive 
associations with increased CRC risk. A suggestive association was observed between 
serum vitamin B12 concentration and increased CRC risk (ORSD=1.21, 95% CI=1.04–
1.42, P=0.016), although potential pleiotropy amongst genetic variants used as 
instruments for this factor constrains the finding. Low blood selenium concentration 
also showed suggestive association with CRC (ORSD=0.85, 95% CI=0.75-0.96, 
P=0.0078), albeit based on a single variant. CRC risk was not associated with any 
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reproductive factor, serum calcium or circulating 25-hydroxyvitamin D 
concentrations.  
 
Interpretation: This analysis highlights a number of modifiable targets for primary 
prevention of CRC, including lifestyle, obesity and cardiometabolic factors that 
should inform public health policy.   
  5 
RESEARCH IN CONTEXT 
 
Evidence before this study: We searched PubMed to identify dietary, lifestyle, 
obesity-related, inflammatory, reproductive and developmental factors that had 
been assessed in observational epidemiological studies potentially influencing 
colorectal cancer (CRC) risk. Studies provide strong evidence for body mass index 
(BMI) and hypercholesterolaemia being associated with increased CRC risk. For most 
other factors there is inconclusive evidence from conventional observational studies 
to reliably establish specific associations. 
 
Added value of this study: Mendelian randomisation exploits germline genetic 
variants as instrumental variables for putative risk factors. Because these genetic 
variants are randomly assorted at conception they are not influenced by reverse 
causation and so can provide evidence for causal relationships. We used genetic 
variants for 39 potentially modifiable CRC risk factors in 26,397 CRC patients and 
41,481 controls. There was suggestive evidence for associations of serum vitamin 
B12, iron and selenium concentrations with CRC. In addition to providing suggestive 
evidence for a causal relationship between higher BMI and increased CRC risk, we 
found evidence for an association between genetically predicted low-density 
lipoprotein with risk of CRC. No associations with CRC risk were identified for any 
reproductive factor. 
 
Implications of all the available evidence: These data provide two main findings: 
Firstly, genetic corroboration of causal relationships between higher BMI and 
hypercholesterolaemia and elevated CRC risk. Secondly, findings support the 
assertion that vitamin B12 supplementation should be limited to individuals with a 
known indication, such as proven deficiency. Our analysis highlights important 
targets for primary prevention of CRC, including lifestyle, obesity and 
cardiometabolic factors. 
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INTRODUCTION 
 
Colorectal cancer (CRC) is the third most common diagnosed malignancy and the 
second leading cause of cancer-related death in the world, accounting for around 1.8 
million new cases and 860,000 deaths in 2018(1). Based on current demographic 
trajectories, it is projected that the global burden of CRC will increase by 72% to over 
3 million new cases and by 82% to 1.6 million cancer deaths annually by 2040(1). 
Differences in CRC incidence between countries and migration studies have 
implicated dietary and other lifestyle factors in CRC development(2). In view of this 
there is increasing interest in developing public health programs to reduce CRC 
incidence by targeting modifiable risk factors. 
 
The World Cancer Research Fund (WCRF) and The American Institute for Cancer 
Research (AICR) have concluded that there is convincing evidence for body mass 
index (BMI) and alcohol intake being causally associated with increased CRC risk, and 
physical activity being causally associated with reduced CRC risk(3). Furthermore, it 
is probable that red meat intake is causally associated with increased CRC risk, 
whereas dietary fibre, dairy products and calcium supplements are causally 
associated with a lower risk(3). For most other factors there is inconclusive evidence 
from these conventional observational studies to reliably establish associations(3). 
 
Much of the available evidence for a causal relationship between potentially 
modifiable factors and CRC risk is derived from observational studies(3), which are 
susceptible to confounding bias and reverse causation(4). Moreover, data from 
randomised trials tend to be scarce and often inconclusive(5, 6). Finally, establishing 
which specific components of risk factors such as diet are important is notoriously 
problematic in conventional observational epidemiological studies(7).  
 
Mendelian randomisation (MR) is an analytical approach, whereby germline genetic 
variants are used as proxies, or instrumental variables, for putative risk factors(8). 
Because these genetic variants are randomly assorted at conception they are not 
influenced by reverse causation, and in the absence of pleiotropy (i.e. genetic 
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variants being associated with the disease through alternative pathways) they can 
provide unconfounded estimates of disease risk(8). Since MR-based studies can 
circumvent many limitations of conventional observational studies the methodology 
is increasingly being employed as an effective strategy to examine the potential 
impact of interventions on disease risk.  
 
We have investigated potentially causal and modifiable CRC risk factors using a two-
sample MR framework (Supplementary Figure 1) whereby genetic variants 
associated with relevant risk factors as instrumental variables were first identified 
from genome-wide association studies (GWAS). We then evaluated the association 
of these instrumental variables with CRC in a large GWAS comprising 26,397 cases of 
CRC and 41,481 control subjects(9). 
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METHODS 
 
Identification of potentially modifiable risk factors 
As well as evaluating dietary, lifestyle, obesity-related, inflammatory, reproductive 
and developmental factors that had been the subject of the report by the WCRF and 
AICR(3), we also searched PubMed to identify additional modifiable CRC risk factors 
that have been reviewed in published epidemiological meta-analyses or MR analyses 
(Supplementary Table 1; Supplementary Information).  
 
Genetic instruments for putative risk factors  
Single nucleotide polymorphisms (SNPs) associated with putative risk factor traits 
suitable for use in MR analysis were identified from the largest GWAS or meta-
analysis of each trait conducted to date (Table 1; Supplementary Table 2; 
Supplementary Information). Traits were only considered if the proportion of 
variance explained (PVE) by the associated SNPs was >0.1%. PVE estimates were 
either obtained from the publication or computed directly from the association 
statistics (Table 1)(10). Suitable genetic instruments were not available for many risk 
factors, such as physical activity, dietary patterns and vitamin C intake, precluding 
their inclusion in this study (Supplementary Table 1). We considered only 
continuous traits, as analysis of binary traits (such as disease status) with binary 
outcomes in two-sample MR frameworks can result in inaccurate causal 
estimates(11). Only SNPs associated with each trait at P<5×10−8 in GWAS of 
European populations with a minor allele frequency >0.01 were considered as 
potential instruments. To mitigate against co-linearity between SNPs, which can bias 
causal effect estimates, we used MR-Base to exclude correlated SNPs at a linkage 
disequilibrium threshold of r2>0.01, retaining those SNPs with the strongest effect on 
the associated trait(12).  
 
Colorectal cancer genotyping data  
To examine the association of each genetic instrument with CRC risk, we used 
summary CRC effect estimates and corresponding standard errors (SEs) from a 
recent meta-analysis of 15 CRC GWAS(9). After imputation, this meta-analysis 
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related >10 million genetic variants to CRC in individuals of European ancestry. UK 
BioBank data were used to obtain genetic instruments for age at menarche, basal 
metabolic rate, birth weight, body fat percentage and waist circumference, as well 
as in one of the CRC GWAS meta-analysed by Law et al.(9). To avoid sample overlap 
biasing this two-sample MR analysis(13) we therefore excluded the UK BioBank CRC 
GWAS and recomputed association statistics using the remaining 14 CRC GWAS 
(Supplementary Table 3) with an inverse variance weighted (IVW) fixed-effects 
model, as described by Law et al.(9).  After exclusion of the UK BioBank CRC GWAS, 
the meta-analysis comprised 26,397 patients and 41,481 controls. SNPs with poor 
imputation quality (i.e. info score <0.8) were not considered in the MR analysis. As 
some potentially modifiable reproductive risk factors are female-specific, where sex 
data were available we further computed CRC association statistics using only 7,952 
female cases and 11,680 female controls. We used MR-Base to harmonize SNPs to 
ensure that the effect estimates of each SNP on each trait and CRC risk 
corresponded to the same allele(12). Effect estimates for the association of each 
trait SNP with CRC risk are shown in Supplementary Table 2. For vitamins, positive 
beta values indicate that the effect allele is associated with increased serum 
concentration. 
 
Statistical analysis 
The MR methodology is predicated on the assumption that genetic variants used as 
instruments for a risk factor are associated with the risk factor and not with a 
confounder or alternative causal pathway (Figure 1). Additionally, to accurately 
estimate the size of the causal effect, the associations depicted in Figure 1 must be 
linear and unaffected by statistical interactions(14). We estimated causal effects for 
each SNP using the Wald ratio (Supplementary Figure 2). For traits with multiple 
SNPs available as instruments, causal effects were estimated using the random-
effects maximum likelihood estimation (MLE-RE) method(15). To assess the 
robustness of our findings, we also obtained weighted median estimates (WME)(16) 
and mode-based estimates (MBE)(17). We used the MR-Egger regression approach 
to evaluate the extent to which directional pleiotropy may affect the causal 
estimates(18). Finally, we conducted leave-one-out analysis using the multiplicative 
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random-effects inverse variance weighted method(12) to examine the impact of 
outlying and pleiotropic SNPs on causal estimates (Supplementary Table 4). I2 
statistics were computed to estimate the proportion of variance across SNPs due to 
heterogeneity (Figure 2; Supplementary Table 5). Results are reported as odds 
ratios (ORSD) and 95% confidence intervals (CIs) per genetically predicted standard 
deviation (SD) unit increase in each putative risk factor. To address the issue of 
multiple testing, we applied a Bonferroni-corrected significance threshold computed 
as 0.0013 (i.e. 0.05/39 putative risk factors). 0.0013<P<0.05 was considered as 
suggestive of a potential association. The power of MR to demonstrate a causal 
effect depends on the proportion of variance in the risk factor explained by the 
genetic variants used as instruments, and we therefore estimated study power at an 
alpha of 0.05 for each risk factor a priori (Table 1)(19). Statistical analyses were 
performed using R v3.4.0 and MR analyses were performed using MR-Base(12). 
 
Role of the funding sources 
Funders had no role in study design, in the collection, analysis and interpretation of 
data, or in writing the report. The corresponding author had full access to all of the 
data and the final responsibility to submit for publication.  
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RESULTS 
 
Diet and lifestyle factors 
Under a MLE-RE model, a suggestive association was seen between genetically 
predicted serum vitamin B12 concentration and higher CRC risk (ORSD=1.21, 95% 
CI=1.04–1.42, P=0.016), however substantial heterogeneity exists between the SNPs 
used as IVs (I2=79.1). Leave-one-out analysis identified SNP rs602662 at a known CRC 
risk locus as having a strong influence on the causal estimate (Supplementary Table 
4)(9). Expression quantitative trait loci analysis has indicated that variation at this 
potentially pleiotropic locus may influence CRC risk through FUT2 and interactions 
with intestinal bacteria and viruses(9). There was a suggestive association between 
genetically predicted greater serum iron concentration and higher CRC risk 
(ORSD=1.17, 95% CI=1.00-1.36, P=0.049), with no outlying genetic variant identified 
(Supplementary Figure 2). There was also a suggestive association between higher 
serum selenium concentration and lower CRC risk (ORSD=0.85, 95% CI=0.75-0.96, 
P=0.0078) albeit based on only one SNP. Genetically predicted alcohol and coffee 
consumption, and blood methionine, zinc, 25-hydroxyvitamin D, carotenoids, 
calcium and vitamins A (retinol), B6 and E concentrations, showed no evidence for 
association with CRC risk (Figure 2). Causal effect estimates for serum vitamin B12 
concentration was similar in sensitivity analyses using the WME and MBE methods 
(Supplementary Table 5). MR-Egger regression showed no evidence of directional 
pleiotropy in the analyses of vitamin B12 or serum iron concentration 
(Supplementary Table 6). The causal effects estimated by MR-Egger were non-
significant for vitamin B12 (Supplementary Table 5), possibly as a result of the 
reduced power of MR-Egger to detect causal effects when compared to other MR 
methodologies(18).  
 
Fatty acid profile and metabolism 
Fatty acid (FA) metabolism involves sequential enzymatic conversions 
(Supplementary Figure 3), and SNPs influencing the metabolism of one FA are 
therefore often associated with circulating concentrations of multiple FAs(20). 
Additionally, many genes involved in FA desaturation and elongation form parts of 
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numerous FA pathways, and hence influence circulating concentrations of multiple 
classes of FA (Supplementary Figure 3). To limit bias introduced by such vertical and 
horizontal pleiotropy, we restricted our analysis to classes of FAs (such as omega-6 
polyunsaturated FAs [PUFAs] and monounsaturated FAs [MUFAs]), rather than 
individual fatty acids, and excluded SNPs known to be associated with multiple FA 
classes (Supplementary Table 7). In this restricted analysis, no association were 
observed for omega-6 PUFA or MUFA concentrations, or for blood levels of the fatty 
acid transport molecule carnitine (Figure 2). After removal of potentially pleiotropic 
SNPs, only a single SNP was suitable for use as an instrumental variable for MUFA 
concentration, prohibiting sensitivity analysis using WME and MBE approaches.  
 
Cardiometabolic and inflammatory factors 
Using information on all genetic variants associated with cardiometabolic factors, we 
observed that measures of obesity and hyperlipidaemia were suggestively associated 
with CRC (Figure 2). Specifically, suggestive associations were seen between 
genetically predicted basal metabolic rate (ORSD=1.10, 95% CI=1.03-1.18, P=0.0079), 
body fat percentage (ORSD=1.14, 95% CI=1.03-1.25, P=0.0086), BMI (ORSD=1.09, 95% 
CI=1.01-1.17, P=0.023) and waist circumference (ORSD=1.13, 95% CI=1.02-1.26, 
P=0.018), and higher odds of CRC. No association between birth weight or 
adiponectin levels and CRC risk was seen (Figure 2). Causal estimates for basal 
metabolic rate, BMI and waist circumference were broadly concordant in sensitivity 
analyses using the WME and MBE methods (Supplementary Table 5).  Conversely, 
the effect estimate for body fat percentage from the MBE approach (ORSD=0.98, 95% 
CI=0.72-1.33, P=0.90) differed in direction to the estimates from other MR 
implementations (Supplementary Table 5), suggesting that some of the instruments 
used to assess the causal effects of body fat percentage may be invalid. MR-Egger 
regression did not identify evidence of horizontal pleiotropy for body fat percentage 
or any other obesity-related trait (Supplementary Table 6). 
 
Genetically predicted low-density lipoprotein (LDL) cholesterol (ORSD=1.14, 95% 
CI=1.04-1.25, P=0.0056) and total cholesterol (ORSD=1.09, 95% CI=1.01-1.18, 
P=0.025) showed suggestive associations with higher odds of CRC. No association 
  13 
between high-density lipoprotein (HDL) cholesterol or total triglyceride levels was 
seen (Figure 2). Similarly, genetically predicted metrics of glycaemia - fasting 
glucose, fasting proinsulin, and HbA1c - were not associated with CRC risk (Figure 2).  
 
Based on a single SNP, a suggestive association was observed between plasma levels 
of interleukin 6 (IL-6) receptor subunit alpha and lower CRC risk (ORSD=0.98, 95% 
CI=0.98-1.00, P=0.035). Associations between circulating C-reactive protein and 
serum immunoglobulin E and CRC risk were not however demonstrated (Figure 2). 
 
Sex hormones and reproduction 
It has been hypothesised that sex-specific differences in CRC incidence may be partly 
attributable to differential sex hormone exposure(21). However, we observed no 
association between age at menarche, a surrogate for endogenous estrogen 
exposure, and CRC risk (ORSD=0.99, 95% CI=0.84-1.18, P=0.92) using CRC data from 
females only. Similarly, we did not observe associations between plasma estradiol 
and progesterone and CRC risk in sex-specific analyses (Figure 2). The genetic 
variants used as instruments for these traits explain only a small proportion of their 
variance (Table 1) and we are therefore unable to exclude a small to moderate effect 
of sex hormone exposure on CRC risk. MR-Egger regression analysis of genetic 
instruments for age at menopause provided evidence of horizontal pleiotropy 
(P=0.01; Supplementary Table 6) and we therefore did not consider this trait in our 
MR analysis. 
 
Developmental and growth factors 
Whilst height is not modifiable once stabilised in adulthood, it is influenced by 
developmental factors and growth processes, which may themselves be modifiable. 
In concordance with evidence reviewed by the WCRF and AICR(3), we observed a 
suggestive association between greater genetically predicted adult height and 
increased odds of CRC (ORSD=1.04, 95% CI=1.00-1.08, P=0.032), further supporting 
the notion that factors during childhood may influence CRC risk. We observed no 
association between plasma insulin-like growth factor 1 (IGF-1) and CRC risk (Figure 
2), although this analysis was conducted using a single genetic variant explaining 
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only a small proportion of IGF-1 variance, and therefore had limited power to detect 
an effect (Table 1). 
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DISCUSSION 
 
With genetic variants as proxies for the putative risk factors, this MR study provides 
suggestive evidence for associations between higher body fat percentage, BMI, waist 
circumference and basal metabolic rate and increased CRC risk. We also found 
suggestive evidence for associations between genetically predicted LDL and total 
cholesterol and risk of CRC, but no evidence of associations with HDL or total 
triglyceride levels. The suggestive association between genetically determined 
higher serum vitamin B12 levels and increased CRC risk is intriguing. There was also 
suggestive evidence for possible associations of genetically predicted serum iron and 
selenium concentrations. 
 
Strengths of this study include examination of multiple factors in relation to CRC risk, 
by exploiting data from large GWAS of risk factors and CRC. Many of the putative risk 
factors considered in this study have not previously been assessed using MR 
frameworks (Supplementary Table 8). Of those factors for which suggestive 
associations were seen (Figure 2), body fat percentage, waist circumference, basal 
metabolic rate, iron status, and blood selenium, serum vitamin B12 and plasma IL-6 
subunit alpha concentrations have not previously been considered in MR analyses of 
CRC risk (Supplementary Table 8). For those CRC risk factors that have previously 
been considered in MR analyses(22) the number of CRC cases and controls we 
consider here affords us greater power to detect causal relationships and allows us 
to more accurately estimate effect magnitudes. For example, while Rodriguez-
Broadbent et al.(23) reported a non-significant association between LDL cholesterol 
and risk of CRC (ORSD=1.05, 95% CI=0.92-1.18, P=0.49), herein a suggestive 
relationship was identified (ORSD=1.14, 95% CI=1.04-1.25, P=0.0056), possibly due to 
increased power of the present analysis. By comparing the results of this study to 
those of previous MR analyses of CRC risk we are also able to identify previously 
reported causal relationships that may represent false positives, such as an 
association between genetically predicted C-reactive protein concentrations and CRC 
risk(24) (Figure 2; Supplementary Table 8).  
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Although F-statistics were high (>10) for all considered traits (Table 1), we cannot 
exclude the possibility that some of our findings may have been affected by weak 
instrument bias. For 19 of the traits for which we identified no association with CRC 
risk, our study had <80% power to identify ORSD<0.91 or >1.10 (Table 1), and we are 
therefore unable to exclude the possibility that these traits have a small effect on 
CRC risk.  
 
As with all MR studies, excluding pleiotropy or an alternative direct causal pathway 
as the basis of association is a challenge. High I2 statistics for many traits indicate the 
presence of such pleiotropy in this analysis (Figure 2). To address this issue we 
implemented the WME and MBE methods, which can provide unbiased causal effect 
estimates even when many genetic variants used represent invalid instruments(16, 
17). For the majority of traits with either a significant or suggestive association with 
CRC risk, the effects estimated were similar using MLE-RE, WME and MBE methods 
(Supplementary Table 5), supporting causal relationships with CRC. It is important to 
note that there exists overlap between the CRC cases and controls considered in this 
study, and those considered in some previous MR analyses(22), and that results from 
this study therefore cannot be considered independent replication.  
 
Our study provides no evidence for an association between genetically predicted 
fasting glucose and proinsulin and risk of CRC, suggesting that metabolic syndrome 
may not influence CRC risk through these factors. However, due to the limited power 
of this analysis, we cannot preclude these factors having small effects on CRC risk 
(Table 1).  
 
Our estimate that an SD increment in adult height increases CRC risk by 4% is 
concordant with many observational studies(3), with greater exposure to growth 
hormones and insulin-like growth factors during childhood being posited as potential 
mechanisms for this association(26). Whilst we observed no significant association 
between plasma IGF-1 and CRC risk (Figure 2), the limited power of this analysis 
means that we are unable to exclude small to moderate effect sizes (Table 1). Taller 
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adults tend to have larger colons, and so greater at-risk cell populations might also 
explain the apparent causal inference. 
 
Of the nutritional factors analysed, a relationship between genetically predicted 
vitamin B12 levels and CRC risk was shown (Supplementary Table 5). Our findings 
are concordant with a randomized trial that found vitamin B12 supplementation 
increases CRC risk(29). Although less convincing, we also found suggestive evidence 
to support high selenium levels having a beneficial effect and greater iron status 
being detrimental (Supplementary Table 5).  
 
Inevitably, further research is required to decipher the biological pathways 
underpinning associations. However, irrespective of the exact functional basis of 
associations using a genetic approach, our analysis highlights important targets for 
primary prevention of CRC in the population. Firstly, between obesity and CRC risk, 
the strong corroboration for obesity being a major risk factor for CRC supports 
reducing the population incidence of obesity a priority. Secondly, our findings are 
consistent with hypercholesterolemia being causally linked to risk and therefore 
support the hypothesis that the increasing use of statins in the population for 
prevention of cardiovascular disease will have the added bonus of reducing CRC 
burden. The limited power of this study to refine robustly the relationship between 
some putative risk factors provides motivation for larger MR studies to demonstrate 
relationships for the spectrum of colorectal neoplasia. Such work may shed 
additional light on other potentially modifiable factors to reduce the overall burden 
of CRC.  
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FIGURES 
 
Figure 1: Principles of Mendelian randomisation and the assumptions that need to 
be satisfied to derive unbiased causal effect estimates. Dashed lines represent 
direct causal and potential pleiotropic effects that would violate Mendelian 
randomisation assumptions. A1: Genetic variants used as instrumental variables are 
associated with the risk factor; A2: Genetic variants influence the risk of colorectal 
cancer only through the risk factor; A3: Genetic variants are not associated with any 
measured or unmeasured confounders. SNP: single nucleotide polymorphism.  
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Figure 2: Odds ratios for associations between genetically predicted risk factors 
and colorectal cancer. Results reported as odds ratios (ORSD) and 95% confidence 
intervals (CIs) per genetically predicted standard deviation (SD) unit increase in the 
risk factor. A maximum likelihood estimate random-effects (MLE-RE) method was 
used to summarize Wald ratio estimates from individual single nucleotide 
polymorphisms (SNPs). IL-6 sRa: interleukin 6 receptor subunit alpha; IGF: insulin-like 
growth factor. * P < 0.05;  ‡ ORSD from restricted analysis, which excludes SNPs 
known to be associated with other classes of fatty acid. † ORSD computed using CRC 
data from female cases and controls.   
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